ArticleOpen medicine (Warsaw, Poland)2025
Integrating experimental and network pharmacology to explore the pharmacological mechanisms of Dioscin against glioblastoma.
Article in Open medicine (Warsaw, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dioscin (Dio) is an important anti-tumor active component found in the seeds of Materials and methods: Using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assays, flow cytometry, and Hoechst staining Results: Dio effectively suppresses the proliferation and promotes apoptosis of U251 cells. In the established tumor-bearing nude mouse model, the anti-cancer activity of Dio was further assessed. Kyoto Encyclopedia of Genes and Genomes enrichment analysis highlighted cancer signaling pathways, including epidermal growth factor receptor (EGFR). Western blot results showed that EGFR phosphorylation and apoptosis gene CASP3 increased with the increase of Dio concentration. Conclusions: Dio could inhibit the proliferation and promote apoptosis of GBM cells, and play a significant inhibitory role in tumor growth. Dio could affect the phosphorylation of EGFR and then trigger the apoptosis process, resulting in the up-regulation of apoptosis protein CASP3 expression in GBM cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.